CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 20 enrolled
Drug / intervention
Fluocinonide Cream 0.1%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01049243
NCT01049243Phase 4Completed
CompareCT.gov

An Open-Label Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis

Wake Forest University Health Sciences·interventional·Posted Jan 14, 2010·Updated Aug 1, 2018

In Brief

A Phase 4 clinical trial evaluating Fluocinonide Cream 0.1% for Atopic Dermatitis. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The purpose of this research study is to better understand how fluocinonide cream 0.1% (Vanos®) works when people use it to treat atopic dermatitis for just a few days.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesUnited States
CollaboratorsMedicis Pharmaceutical Corporation

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 14, 2010
Enrollment StartMar 1, 2009
Primary CompletionSep 1, 2009
Study CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 16.5 years ago

Interventions

Fluocinonide Cream 0.1%drug

0.1% Cream, One Application, Twice Daily, 14 Days